Consensus Myriad Genetics, Inc.

Stocks

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-08-28 EDT			5-day change	1st Jan Change
3.160 ^USD	-0.63%		-1.25%	-48.62%

07-30	Myriad Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026
07-30	Myriad Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

c513f8854fe92cd0.rzswezsFH79kuYPXt93qnuPwXggNaSjGQSelyFtNZXg.xF51TVl_WIhd6vaA0eqE0JeYJGBMGRilN1DtphIlHCHbfF8WFih9jSXNsw~b2fb8c4bcfbe933a856e1ddd9582b6b0

Analysts' recommendations: Myriad Genetics, Inc.

02-24	UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating	MT
11-04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
25-08-07	UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating	MT
25-08-06	Top Midday Gainers	MT
25-05-21	Myriad Genetics Shares Fall After Downgrade From Scotiabank	MT
25-05-21	Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	MT
25-05-19	Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating	MT
25-05-08	Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform	MT
25-05-07	UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating	MT
25-05-07	Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22	MT
25-04-09	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT
25-03-12	Myriad Genetics Shares Rise After Upgrade From Piper Sandler	MT
25-03-12	Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	MT
25-02-25	UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	MT
24-12-09	Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	MT
24-11-18	Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	MT
24-09-19	Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	MT
24-09-19	Morgan Stanley Initiates Myriad Genetics at Equalweight	MT
24-08-28	Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	MT
24-06-27	Scotiabank Initiates Myriad Genetics at Sector Outperform	MT
24-05-13	Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	MT
24-01-29	Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	MT
24-01-29	BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	MT
23-12-19	Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	MT
23-12-13	Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	MT

More recommendations

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
MYRIAD GENETICS, INC.	-	+19.26%
GUARDANT HEALTH, INC.		+20.3%
BIOMÉRIEUX		+5.04%
10X GENOMICS, INC.		-19.5%
CARIS LIFE SCIENCES, INC.		+5.35%
LANTHEUS HOLDINGS, INC.		+6.34%
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.		+26.66%
DIASORIN S.P.A.		-6.47%
AUTOBIO DIAGNOSTICS CO., LTD.		+15.47%
Average		+8.05%
Weighted average by Cap.		+8.89%